Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment
about
Rethinking biologics in lupus nephritis.Solving Immunology?Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].ImmPort, toward repurposing of open access immunological assay data for translational and clinical research.
P2860
Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Reanalysis of the Rituximab in ...... marker of successful treatment
@ast
Reanalysis of the Rituximab in ...... marker of successful treatment
@en
Reanalysis of the Rituximab in ...... marker of successful treatment
@nl
type
label
Reanalysis of the Rituximab in ...... marker of successful treatment
@ast
Reanalysis of the Rituximab in ...... marker of successful treatment
@en
Reanalysis of the Rituximab in ...... marker of successful treatment
@nl
prefLabel
Reanalysis of the Rituximab in ...... marker of successful treatment
@ast
Reanalysis of the Rituximab in ...... marker of successful treatment
@en
Reanalysis of the Rituximab in ...... marker of successful treatment
@nl
P2093
P2860
P3181
P1476
Reanalysis of the Rituximab in ...... marker of successful treatment
@en
P2093
Atul J Butte
Bjoern Hartmann
Jeffrey Wiser
Mazen Nasrallah
Patrick Dunn
P2860
P2888
P3181
P356
10.1186/S13075-015-0778-Z
P407
P577
2015-09-21T00:00:00Z
P5875
P6179
1031542551